Mal Eutick News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Final Results of Bioavailability Study of Phebra's Oral Arsenic Capsule for Acute Promyelocytic Leukaemia (APL) Confirm Bioequivalence of Oral and IV Formulations News provided by Share this article SYDNEY, May 13, 2021 /PRNewswire/ -- Australian pharmaceutical group Phebra (' Company') congratulates the Australasian Leukaemia and Lymphoma Group (ALLG) on the release of their abstract EP433 at the virtual European Hematology Association (EHA) 2021 Conference. The abstract builds on the initial bioequivalence data from the first phase of the trial, published at EHA in June 2019 and reveals th...

SYDNEY, May 14, 2021 /PRNewswire/ — Australian pharmaceutical group Phebra (‘ Company‘) congratulates the Australasian Leukaemia and Lymphoma Group (ALLG) on the release of their abstract EP433 at the virtual European Hematology Association (EHA) 2021 Conference. The abstract builds on the initial bioequivalence data from the first phase of the trial, published at EHA in June 2019 and reveals the final results from the ALLG APML5 bioavailability study undertaken by the ALLG at hospitals across Australia in 31 patients with previously untreated APL. The aim of the APML5 study, was to c...